文献速递骨质疏松与钙磷/甲状旁腺垂体与肾上腺疾病

慢性甲状旁腺功能减退症患者骨脆性的管理策略

Approach to the patient: management of bone fragility in patients with chronic hypoparathyroidism.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

本文综述慢性甲状旁腺功能减退症(HypoPT)患者骨重建变化及骨脆性管理。HypoPT导致低骨转换,骨折风险可能增加,但骨质疏松治疗缺乏骨折风险降低证据。传统治疗下用强效抗骨吸收药需密切监测低钙血症,特立帕肽可能短期最佳;长期PTH替代者发生脆性骨折时或应使用抗骨吸收药。

要点

  • HypoPT患者骨密度正常或偏高但骨折风险可能增加。
  • 传统治疗下用双膦酸盐或地舒单抗需警惕低钙血症。
  • 特立帕肽可能是短期最佳选择,长期PTH替代者骨折时或可用抗骨吸收药。

核心结论

  • 慢性HypoPT患者骨脆性管理挑战大,缺乏骨折风险降低的临床证据。
  • 传统治疗下强效抗骨吸收药可能致低钙血症,需密切监测。
  • 特立帕肽可能短期最佳;长期PTH替代者脆性骨折时或应用抗骨吸收药。

研究设计与样本

  • 本文为针对患者的综述,描述慢性HypoPT骨重建与骨强度变化及治疗选择。

主要发现

  • 慢性HypoPT导致低骨转换,骨密度正常或偏高但可能损害骨强度。
  • 近期研究提示HypoPT患者骨折风险可能增加。
  • 传统治疗下强效抗骨吸收药因抗重建作用可能致低钙血症,对骨材料特性影响未知。

临床怎么用

  • 传统治疗下用双膦酸盐或地舒单抗需密切监测低钙血症。
  • 特立帕肽可能是短期最佳选择。
  • 长期PTH替代者发生脆性骨折时或应使用抗骨吸收药,但最佳方案未知。

局限性

  • 管理骨脆性缺乏骨折风险降低的临床证据。
  • 抗骨吸收药对骨材料特性的影响未知。
  • 长期PTH替代者抗骨吸收药的最佳治疗方案安全性和疗效未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Parathyroid hormone is the main hormonal regulator of bone remodeling; thus, chronic hypoparathyroidism (HypoPT) leads to low bone turnover that might compromise bone strength, despite the normal or even high bone mineral density. Recent studies suggest that fracture risk might be increased in patients with HypoPT. Given that all available treatments for osteoporosis affect bone remodeling, management of bone fragility of any etiology in patients with HypoPT is challenging and lacks clinical evidence in terms of fracture risk reduction. In the present article, we describe the changes in bone remodeling and bone strength in patients with chronic HypoPT managed by conventional therapy and under PTH replacement. In addition, based on pathophysiology and the limited existing evidence, we discuss which osteoporosis medication could be used in patients with HypoPT and concurrent increased bone fragility. In HypoPT patients under conventional treatment with calcium and active vitamin D, administration of potent antiresorptives (bisphosphonates, denosumab) should be done under close monitoring, given their antiremodeling action that might result in hypocalcemia; the effect on bone material properties is not known. Teriparatide is probably the best available option, at least in the short term. In contrast, patients with HypoPT on long-term PTH replacement therapy who experience fragility fractures should probably be treated with antiresorptives, although the optimal therapeutic regimen, in terms of safety and efficacy, is yet unknown.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Tournis S, Kassi E, Palermo A, et al. Approach to the patient: management of bone fragility in patients with chronic hypoparathyroidism. J Clin Endocrinol Metab. 2026. PMID: 41968412. doi:10.1210/clinem/dgag160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。